Ron in the News

Immunotherapy could be the “fourth pillar” of cancer treatments

Jim Allison, today’s winner of the first Nobel prize for cancer therapy along with Kyoto University’s Tasuku Honjo, says he expects immunotherapy to be the “fourth pillar” in cancer treatments, along with radiation, chemotherapy and other gene-targeting treatments. Why it matters: Immunotherapy treatments for cancer had a slow start, but persistent research has led to …

Immunotherapy could be the “fourth pillar” of cancer treatments Read More »

Ron DePinho raises seed cash for MD Anderson colleague’s work on a ‘Holy Grail molecule’ in cancer, inflammation

Ron DePinho has blazed a wide trail in cancer research. As founding director of the Belfer Institute for Applied Cancer Science at Dana-Farber and former president of MD Anderson Cancer Center in Houston — where he departed after a rocky tenure which he now fiercely defends — DePinho spearheaded translational programs and managed, among other things, to …

Ron DePinho raises seed cash for MD Anderson colleague’s work on a ‘Holy Grail molecule’ in cancer, inflammation Read More »

Former M.D. Anderson president’s new Houston company secures funding, seeks CEO

Houston-based biopharmaceutical company Tvardi Therapeutics Inc., which was co-founded by former University of Texas M.D. Anderson Cancer Center president Dr. Ronald DePinho, secured $9 million in a Series A financing round. Tvardi develops a cancer drug that acts as an inhibitor to STAT3 — a signaling molecule that, when left unrestrained, can sometimes lead to …

Former M.D. Anderson president’s new Houston company secures funding, seeks CEO Read More »

Biotech Tvardi Therapeutics raises $9M series A for STAT3 inhibitors

With $9 million in series A financing, Tvardi Therapeutics has enough runway to finish a phase 1 trial of its lead asset, an oral STAT3 inhibitor, in solid tumors and to start multiple proof-of-concept studies in additional cancer indications. The Houston-based startup hopes to finish the phase 1 trial by mid-2019 and to start its …

Biotech Tvardi Therapeutics raises $9M series A for STAT3 inhibitors Read More »

PALCUS announces honorees for Leadership Awards

WASHINGTON — An internationally known cancer researcher, the first female superintendent of the Rhode Island State Police, a champion for world language education and a relentless immigrant advocate are among those who will recognized at the 22nd Annual Portuguese-American Leadership Council of the United States (PALCUS) Awards Gala. “This year, as in years past, our …

PALCUS announces honorees for Leadership Awards Read More »

HPV vaccination rates show progress, but off track for 2020 goal

In 2006, a safe and effective human papillomavirus (HPV) vaccine became available to protect against cancers caused by HPV infection. HPV vaccination rates in adolescent boys and girls are rising, though still not fast enough, with HPV-linked cancer cases soaring by nearly 45% between 1999 and 2015. Fewer than half of American adolescents have been …

HPV vaccination rates show progress, but off track for 2020 goal Read More »

HPV-related cancer rates are rising. So are vaccine rates — just not fast enough

Cancers linked to the human papillomavirus have increased significantly over the last 15 years in the United States, with throat cancer now the most common HPV-related malignancy, the Centers for Disease Control and Prevention reported Thursday. More than 43,000 people developed HPV-associated cancer in 2015, compared with about 30,000 in 1999, the CDC said. At …

HPV-related cancer rates are rising. So are vaccine rates — just not fast enough Read More »

Get Insights From Ron

Sign up for the latest news and updates from Ron DePinho, MD